Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Prospective, Randomized, Double-masked, Parallel Group, Multi-center Study Assessing the Safety and Efficacy of 2% Rebamipide (OPC-12759) Compared to Placebo in Clearing of Fluorescein Staining of the Central Cornea in Subjects With Keratoconjunctivitis Sicca (Dry Eye)

NCT01057147 is registered in ClinicalTrials.gov with Kubota Vision Inc. as lead sponsor.

NCT NCT01057147
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01057147 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Prospective, Randomized, Double-masked, Parallel Group, Multi-center Study Assessing the Safety and Efficacy of 2% Rebamipide (OPC-12759) Compared to Placebo in Clearing of Fluorescein Staining of the Central Cornea in Subjects With Keratoconjunctivitis Sicca (Dry Eye)
Lead sponsor
Kubota Vision Inc.
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2010
Completion date
February 28, 2011
Enrollment
116 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

dry eye, keratoconjunctivitis sicca